Nimesulide |
1 mM |
|
rat; Sprague-Dawley Crl:CD (SD) BR |
lung microsomes |
adrenochrome assay (Misra and Fridovich, 1972) |
Positive |
p < 0.05 |
11 |
Nimesulide |
0.5 mM |
20 minutes |
rat; Sprague-Dawley Crl:CD (SD) BR |
lung microsomes |
horseadish preoxidase method (Green and Hill, 1984) |
Positive |
p < 0.05 |
11 |
Zidovudine |
|
|
|
|
|
Positive |
|
307 |
Acyclovir |
|
|
|
|
|
Positive |
|
307 |
Ganciclovir |
|
|
|
|
|
Positive |
|
307 |
Zalcitabine |
|
|
|
|
|
Positive |
|
307 |
Sulindac |
|
|
|
|
|
Positive |
|
45 |
Ciprofloxacin |
|
|
|
|
|
Positive |
|
307 |
Cisplatin |
|
|
|
|
|
Positive |
|
307 |
Cyclophosphamide |
|
|
|
|
|
Positive |
|
307 |
Paraquat |
10 mM |
|
yeast; EG103 (Wild-type) |
mitochondria |
Measurement of superoxide anion |
Negative |
|
14 |
Paraquat |
10 mM |
|
yeast; EG103 (Wild-type) |
mitochondria |
Measurement of superoxide anion; Used ethanol (5 mM) as substrate |
Negative |
|
14 |
Paraquat |
10 mM |
|
yeast; EG110 (MnSOD knock-out) |
mitochondria |
Measurement of superoxide anion; Used ethanol (5 mM) as substrate |
Positive |
|
14 |
Paraquat |
10 mM |
|
yeast; EG103 (Wild-type) |
mitochondria |
Measurement of superoxide anion; Used ethanol (5 mM) as substrate |
Positive |
|
14 |
Paraquat |
10 mM |
|
yeast; EG103 (Wild-type) |
mitochondria |
Measurement of superoxide anion; Used ethanol (5 mM) as substrate; Used FCCP (1μm) as uncoupler |
Negative |
|
14 |
Paraquat |
1 mM |
10 minutes |
rat |
isolated heart mitochondria |
Measurement of superoxide anion; Used glutamate/malate (5 mM) as substrate |
Positive |
|
14 |
Paraquat |
1 mM |
10 minutes |
rat |
isolated heart mitochondria |
Measurement of superoxide anion; Used glutamate/malate (5 mM) as substrate; Used FCCP (1μm) as uncoupler |
Negative |
|
14 |
Paraquat |
0.1 mM |
10 minutes |
rat |
isolated heart mitochondria |
Measurement of superoxide anion; Used succinate (5 mM) as substrate |
Positive |
|
14 |
Paraquat |
1 mM |
10 minutes |
rat |
isolated heart mitochondria |
Measurement of superoxide anion; Used succinate (5 mM) as substrate; Used FCCP (1μm) as uncoupler |
Negative |
|
14 |
Paraquat |
0.1 mM |
10 minutes |
rat |
isolated heart mitochondria |
Measurement of superoxide anion; Used succinate (5 mM) as substrate; Used rotenone (4μm) as inhibiter |
Negative |
|
14 |
Paraquat |
1 mM |
10 minutes |
rat |
isolated heart mitochondria |
Measurement of hydrogen peroxide; Used glutamate/malate (5 mM) as substrate |
Positive |
|
14 |
Paraquat |
1 mM |
10 minutes |
rat |
isolated heart mitochondria |
Measurement of hydrogen peroxide; Used succinate (5 mM) as substrate |
Positive |
|
14 |
Caffeine |
> 100 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Negative |
MEC |
306 |
citrate |
> 100 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Negative |
MEC |
306 |
Etoposide |
> 100 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Negative |
MEC |
306 |
Metformin |
500 μM |
24 hours |
human |
hepatocytes |
ROS measurement |
Negative |
|
15 |
Metformin |
1 mM |
24 hours |
human |
hepatocytes |
ROS measurement |
Positive |
|
15 |
Metformin |
2 mM |
24 hours |
human |
hepatocytes |
ROS measurement |
Positive |
|
15 |
buformin |
75 μM |
24 hours |
human |
hepatocytes |
ROS measurement |
Positive |
|
15 |
Phenformin |
12.5 μM |
24 hours |
human |
hepatocytes |
ROS measurement |
Positive |
|
15 |
Rotenone |
100 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Positive |
MEC |
306 |
Amiodarone |
10 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Positive |
MEC |
306 |
Chlorpromazine |
50 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Positive |
MEC |
306 |
Cyclosporin A |
5 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Positive |
MEC |
306 |
imipramine |
50 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Positive |
MEC |
306 |
Maprotiline |
5 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Positive |
MEC |
306 |
Tamoxifen |
5 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Positive |
MEC |
306 |
Troglitazone |
10 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Positive |
MEC |
306 |
atorvastatin |
100 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Positive |
MEC |
306 |
Cerivastatin |
5 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Positive |
MEC |
306 |
fluvastatin |
50 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Positive |
MEC |
306 |
Acetylsalicylic acid |
5 μmol/ml |
24 hours |
human |
HepG2 |
ROS measurement |
Negative |
p < 0.05 |
2 |
Acetylsalicylic acid |
5 μmol/ml |
48 hours |
human |
HepG2 |
ROS measurement |
Negative |
p < 0.05 |
2 |
Acetylsalicylic acid |
10 μmol/ml |
24 hours |
human |
HepG2 |
ROS measurement |
Positive |
p < 0.05 |
2 |
Acetylsalicylic acid |
10 μmol/ml |
48 hours |
human |
HepG2 |
ROS measurement |
Positive |
p < 0.05 |
2 |
lovastatin |
10 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Positive |
MEC |
306 |
pravastatin |
50 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Positive |
MEC |
306 |
Simvastatin |
5 µM |
1 hour |
Human |
HepG2 |
High-content screening assay |
Positive |
MEC |
306 |